This analysis is even more valuable in light of the EMBRACA trial results, in which talazoparib provided a significant PFS improvement over standard chemotherapy in patients with BRCA-related HER2-negative advanced breast cancer, at the same level in both TNBC and hormone-receptor-positive subtypes [32]. This evidence concerns the gene NR4A1 and breast cancer.